Can NGAL be employed as prognostic and diagnostic biomarker in human cancers? A systematic review of current evidence Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Sunday, January 22, 2017

Can NGAL be employed as prognostic and diagnostic biomarker in human cancers? A systematic review of current evidence



 Because of its small molecular size and resistance to degradation, NGAL is readily excreted and detected in the urine
                       ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
abstract:
Can NGAL be employed as prognostic and diagnostic biomarker in human cancers? A systematic review of current evidence
 

BACKGROUND:

Some studies have reported differentially altered neutrophil gelatinase-associated lipocalin (NGAL) levels in several malignancies. We evaluated NGAL measured in plasma or urine as both prognostic and diagnostic marker for different types of human tumors.

RESULTS:

We included 35 studies dedicated to colorectal, pancreas, breast, thyroid, gastric, kidney, endometrial, brain, liver, lung, esophageal, oral and ovarian cancers......

CONCLUSIONS:

NGAL determination in plasma and urine could be useful in the prognosis of colorectal and breast cancer, but its prognostic accuracy remains uncertain for other human tumors.


0 comments :

Post a Comment

Your comments?